Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer

British Journal of Cancer

Volumn 107, Issue 12, 2012, Pages 1950-1955

  Baba, H ^a   Watanabe, M ^a   Okabe, H ^a   Miyamoto, Y ^a   Sakamoto, Y ^a   Baba, Y ^a   Iwatsuki, M ^a   Chikamoto, A ^a   Beppu, T ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

DPD; ERCC1; metastatic colorectal cancer; National Cancer Institute; oxaliplatin

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER RESECTION; MALE; METASTASIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; DRUG COMBINATIONS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); ORGANOPLATINUM COMPOUNDS; OXONIC ACID; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, MESSENGER; TEGAFUR; UNITED STATES; UP-REGULATION;

EID: 84870803143     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.502     Document Type: Article

References (28)

1. Al-Mulla F, Going JJ, Sowden ET, Winter A, Pickford IR, Birnie GD (1998)Heterogeneity of mutant versus wild-type Ki-ras in primary andmetastatic colorectal carcinomas, and association of codon-12 valinewith early mortality. J Pathol 185: 130-138
2. Baba H, Muro K, Yasui H, Shimada Y, Tsuji A (2011) Updated results of theFIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI)versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastaticcolorectal cancer (mCRC). J Clin Oncol 29: 2011 (Suppl; Abstract 3562)
3. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE(2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CAmutations in primary colorectal adenocarcinomas and their correspondingmetastases. Clin Cancer Res 16: 790-799
4. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M,Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H (2007)Identification of stem cells in small intestine and colon by marker geneLgr5. Nature 449: 1003-1007
5. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV,Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV(2006) ERCC1 and RRM1 gene expressions but not EGFR are predictiveof shorter survival in advanced non-small-cell lung cancer treated withcisplatin and gemcitabine. Ann Oncol 17: 1818-1825
6. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R,Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, HeraitP (1998) Randomised trial of irinotecan plus supportive care versussupportive care alone after fluorouracil failure for patients withmetastatic colorectal cancer. Lancet 352: 1413-1418
7. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A,Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF(2007) Phenotypic characterization of human colorectal cancer stemcells. Proc Natl Acad Sci USA 104: 10158-10163
8. Estellar M (2003) Relevance of DNA methylation in the management ofcancer. Lancet Oncol 4: 351-358
9. Giaretti W, Monaco R, Pujic N, Rapallo A, Nigro S, Geido E (1996)Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas:association with degree of DNA aneuploidy. Am J Pathol 149:237-245
10. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, FieldsJZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a markerfor normal and malignant human colonic stem cells (SC) and tracks SCoverpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389
11. Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH,Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ, Kim NK (2009) Biomarkeranalysis in stage III-IV (M0) gastric cancer patients who receivedcurative surgery followed by adjuvant 5-fluorouracil and cisplatinchemotherapy: epidermal growth factor receptor (EGFR) associated withfavourable survival. Br J Cancer 100: 732-738
12. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, VallbohmerD, Park S, Danenberg KD, Takasaki K, Danenberg PV (2006) Vascularendothelial growth factor messenger RNA expression level is preservedin liver metastases compared with corresponding primary colorectalcancer. Clin Cancer Res 12: 29-33
13. Lentz F, Tran A, Rey E, Pons G, Treluyer JM (2005) Pharmacogenomics offluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectalcancer: clinical implications. Am J Pharmacogenomics 5: 21-33
14. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression datausing real-timequantitative PCR and the 2(-Delta Delta C(T)) Method.Methods 25: 402-408
15. Losi L, Baisse B, Bouzourene H, Benhattar J (2005) Evolution ofintratumoral genetic heterogeneity during colorectal cancer progression.Carcinogenesis 26: 916-922
16. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T,Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, TokunagaS, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K(2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plusirinotecan (FOLFIRI) as second-line chemotherapy for metastaticcolorectal cancer: a randomised phase 2/3 non-inferiority study (FIRISstudy). Lancet Oncol 11: 853-860
17. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancercell capable of initiating tumour growth in immunodeficient mice.Nature 445: 106-110
18. O'Neil BH, Goldberg RM (2008) Innovations in chemotherapy formetastatic colorectal cancer: an update of recent clinical trials. Oncologist13: 1074-1083
19. Okabe H, Arakawa K, Takechi T, Fukushima M (2000) Expression ofrecombinant human dihydropyrimidine dehydrogenase and its applicationto the preparation of anti-DPD antibodies for immunochemicaldetection. Gan To Kagaku Ryoho 27: 891-898
20. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R (2009) Colon cancer stemcells. J Mol Med (Berl) 87: 1097-1104
21. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C,De Maria R (2007) Identification and expansion of human colon- cancerinitiatingcells. Nature 445: 111-115
22. Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, Hua A,Mery-Mignard D (2002) Antitumour activity of three second-linetreatment combinations in patients with metastatic colorectal cancerafter optimal 5-FU regimen failure: a randomised, multicentre phase IIstudy. Ann Oncol 13: 1558-1567
23. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R,Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C(1998) Randomised trial of irinotecan versus fluorouracil by continuousinfusion after fluorouracil failure in patients with metastatic colorectalcancer. Lancet 352: 1407-1412
24. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD,Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, SchneiderPM, Danenberg PV (2005) Downregulation of TS, DPD, ERCC1, GST-Pi,EGFR, and HER2 gene expression after neoadjuvant three-modalitytreatment in patients with esophageal cancer. J Am Coll Surg 200:336-344
25. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D,Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C,de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reversesequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol 22: 229-237
26. van der Flier LG, Haegebarth A, Stange DE, van de Wetering M,Clevers H (2009) OLFM4 is a robust marker for stem cells in humanintestine and marks a subset of colorectal cancer cells. Gastroenterology137: 15-17
27. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K,Iinuma H, Ikeuchi H, Eshima K (2011a) Differential gene expressionsignatures between colorectal cancers with and without KRAS mutations:crosstalk between the KRAS pathway and other signalling pathways. EurJ Cancer 47: 1946-1954
28. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K,Iinuma H, Shibuya H, Eshima K (2011b) Heterogeneity of KRAS statusmay explain the subset of discordant KRAS status between primary andmetastatic colorectal cancer. Dis Colon Rectum 54: 1170-1178